The Integration of Real World Evidence Analytics in Modern Pharma In the landscape of 2026, the success of a new therapeutic agent is increasingly dictated by the depth of real world evidence analytics applied during the pre-launch phase. Commercial pharmaceutical insights have shifted from traditional survey-based models to longitudinal data streams that capture patient outcomes in diverse...

As 2026 begins, the global hepatology community is closely monitoring a wave of breakthrough data from Phase II and III trials that aim to permanently correct the ATP7B genetic mutation. Regulatory authorities in the European Union and the United States have recently signaled a willingness to accept biomarker-driven endpoints, such as long-term reduction in non-ceruloplasmin bound copper, to...

The High Throughput Screening Market is on an upward trajectory, with projections indicating a market size of approximately USD 64.4 billion by 2035, growing at a compound annual growth rate (CAGR) of 9.70%. This growth is fueled by an increasing need for rapid drug discovery processes, as healthcare demands for personalized medicine continue to rise. Drug discovery, the largest application...